These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 10092690

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease.
    Moayyedi P, Congleton J, Page RL, Pearson SB, Muers MF.
    Thorax; 1995 Aug; 50(8):834-7. PubMed ID: 7570433
    [Abstract] [Full Text] [Related]

  • 23. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD.
    Cazzola M, Santus P, D'Adda A, Pizzolato S, Di Marco F, Centanni S.
    Pulm Pharmacol Ther; 2009 Jun; 22(3):177-82. PubMed ID: 19038356
    [Abstract] [Full Text] [Related]

  • 24. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81.
    Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, Windom H, Beasley R.
    Thorax; 1990 Mar; 45(3):170-5. PubMed ID: 2330548
    [Abstract] [Full Text] [Related]

  • 25. Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance.
    Taylor RG, Pavia D, Agnew JE, Lopez-Vidriero MT, Newman SP, Lennard-Jones T, Clarke SW.
    Thorax; 1986 Apr; 41(4):295-300. PubMed ID: 2943050
    [Abstract] [Full Text] [Related]

  • 26. Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomized trial.
    Nouira S, Bouida W, Grissa MH, Beltaief K, Trimech MN, Boubaker H, Marghli S, Letaief M, Boukef R.
    Am J Ther; 2014 Apr; 21(3):152-8. PubMed ID: 22407196
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Asthma and COPD medicines prescription-claims: A time-series analysis of England's national prescriptions during the COVID-19 pandemic (Jan 2019 to Oct 2020).
    Barrett R, Barrett R.
    Expert Rev Respir Med; 2021 Dec; 15(12):1605-1612. PubMed ID: 34555287
    [Abstract] [Full Text] [Related]

  • 29. Death from airways obstruction: accuracy of certification in Northern Ireland.
    Smyth ET, Wright SC, Evans AE, Sinnamon DG, MacMahon J.
    Thorax; 1996 Mar; 51(3):293-7. PubMed ID: 8779134
    [Abstract] [Full Text] [Related]

  • 30. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 31. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
    Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ.
    Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
    [Abstract] [Full Text] [Related]

  • 32. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
    Singh S, Loke YK, Furberg CD.
    JAMA; 2008 Sep 24; 300(12):1439-50. PubMed ID: 18812535
    [Abstract] [Full Text] [Related]

  • 33. [The effect of inhaled anticholinergic drugs (tiotropium bromide) on asthma patients with persistent obstructive ventilatory impairment].
    Nogami H, Honjo S, Iwanaga T.
    Arerugi; 2012 Nov 24; 61(11):1675-82. PubMed ID: 23328224
    [Abstract] [Full Text] [Related]

  • 34. Thermogenic effect of bronchodilators in patients with chronic obstructive pulmonary disease.
    Burdet L, de Muralt B, Schutz Y, Fitting JW.
    Thorax; 1997 Feb 24; 52(2):130-5. PubMed ID: 9059472
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Inhaled drugs as risk factors for community-acquired pneumonia.
    Almirall J, Bolíbar I, Serra-Prat M, Palomera E, Roig J, Hospital I, Carandell E, Agustí M, Ayuso P, Estela A, Torres A, Community-Acquired Pneumonia in Catalan Countries.
    Eur Respir J; 2010 Nov 24; 36(5):1080-7. PubMed ID: 20525710
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma.
    Ulrik CS, Frederiksen J.
    Chest; 1995 Jul 24; 108(1):10-5. PubMed ID: 7606941
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.